>If an intervention is shown to be effective in treating COVID-19, the design allows the replacement of the placebo group with the effective intervention. Is't

>If an intervention is shown to be effective in treating COVID-19, the design allows the replacement of the placebo group with the effective intervention. Is't that kind of bad? Say, if by pure chance, there is an intervention that is equally effective as Ivermectin, wouldn't it cause the whole thing to zero out, or show very little benefit for the Ivermectin? EDIT: They also say.. > It would not take much of a clinical trial to know whether that was true or not, and almost every physician would be able to spot really quickly whether there was a drug that miraculously was helping people. But we’re not getting that feedback from physicians Isn't that the exact kind of feedback that is being neglected right now?